HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: As with TSA, SAHA inhibits class I and II HDACs, and was the first FDA-approved HDAC inhibitor for the treatment of refractory cutaneous T-cell lymphoma (CTCL) [17].